Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Galectin Therapeutics Inc shares valued at $94,643 were sold by LEWIS JOEL on Nov 17 ’25. At $6.04 per share, LEWIS JOEL sold 15,680 shares. The insider’s holdings dropped to 832,592 shares worth approximately $4.75 million following the completion of this transaction.
Also, LEWIS JOEL sold 6,783 shares, netting a total of over 41,723 in proceeds. Following the sale of shares at $6.15 each, the insider now holds 832,592 shares.
Before that, CALLICUTT JACK W had sold 46,310 shares from its account. In a trade valued at $288,187, the Chief Financial Officer traded Galectin Therapeutics Inc shares for $6.22 each. Upon closing the transaction, the insider’s holdings decreased to 46,310 shares, worth approximately $43399.8.
Analysts at H.C. Wainwright resumed the stock at ‘”a Buy”‘ outlook in a report released in mid August. As of February 13, 2019, B. Riley FBR has initiated its “Buy” rating for GALT. Earlier on December 07, 2017, H.C. Wainwright resumed its rating. Their recommendation was “a Buy” for GALT stock.
Analyzing GALT Stock Performance
On last trading session, Galectin Therapeutics Inc [NASDAQ: GALT] rose 4.40% to $5.7. The stock’s lowest price that day was $5.43, but it reached a high of $5.95 in the same session. During the last five days, there has been a drop of approximately -0.18%. Over the course of the year, Galectin Therapeutics Inc shares have jumped approximately 97.23%. Shares of the company reached a 52-week high of $6.55 on 09/12/25 and a 52-week low of $1.07 on 01/14/25.
Support And Resistance Levels for Galectin Therapeutics Inc (GALT)
According to the 24-hour chart, there is a support level at 5.44, which, if violated, would cause prices to drop to 5.17. In the upper region, resistance lies at 5.96. The next price resistance is at 6.21. RSI (Relative Strength Index) is 53.96 on the 14-day chart, showing neutral technical sentiment.
Is Galectin Therapeutics Inc subject to short interest?
Stocks of Galectin Therapeutics Inc saw a sharp steep in short interest on 2025-11-14 dropping by -1.63 million shares to 6.76 million. Data from Yahoo Finance shows that the short interest on 2025-10-15 was 8.39 million shares. A decline of -24.09% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 17.71 of the overall float, the days-to-cover ratio (short ratio) decline to 17.71.
Which companies own the most shares of Galectin Therapeutics Inc (GALT)?
On November 28, 2017, H.C. Wainwright assigned a price target of “a Buy” to the stock and reiterated coverage with a $6.
